MedTrace Logo

A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles

NCT00631124 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2014-12-02

No results posted yet for this study

Summary

Investigation of a new pill containing an estrogen and a progestin in order to monitor the inhibition of the ovulation in young healthy females over 3 treatment cycles

Conditions

  • Contraception

Interventions

DRUG

BAY86-4891 (Estradiol / Drospirenone)

Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles

DRUG

BAY86-4891 (Estradiol / Drospirenone)

Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-10-31
Completion
2008-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00631124 on ClinicalTrials.gov